logo-loader
ReNeuron Group PLC

Exercise of options, PDMR dealing and TVR

/**/ h1{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;font-weight:bold;}h2{margin:0cm;margin-bottom:.0001pt;font-size:16.0pt;font-family:"Times New Roman","serif";color:windowtext;font-weight:bold;}h3{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;font-weight:bold;}h4{margin:0cm;margin-bottom:.0001pt;text-align:center;font-size:16.0pt;font-family:"Times New Roman","serif";color:windowtext;font-weight:bold;}h5{margin:0cm;margin-bottom:.0001pt;text-align:justify;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;font-weight:bold;}h6{margin:0cm;margin-bottom:.0001pt;text-align:right;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;font-weight:bold;}p{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";color:black;}ol{margin-bottom:0cm;}ul{margin-bottom:0cm;}link{ color: blue } visited{ color: purple } .bc{size:595.3pt 841.9pt;margin:56.75pt 106.25pt 2.0cm 90.0pt;}div.bc{}h1.db{text-indent:117.0pt}span.dc{font-weight:normal}p.a,li.a,div.a{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;}table.de{margin-left:-5.4pt;border-collapse:collapse}td.cz{width:210.6pt;padding:0cm 5.4pt 0cm 5.4pt}span.da{font-size:11.0pt;font-family:"Calibri","sans-serif"}td.cw{width:9.0cm;padding:0cm 5.4pt 0cm 5.4pt}h3.cx{text-align: right} span.cy{font-size:11.0pt; font-family:"Calibri","sans-serif"}h2.cu{text-align: center}p.df{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;text-align: center}p.dg{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;font-weight: bold; text-align: center}p.dh{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;margin-right:1.45pt;text-align:justify}span.cr{font-size:11.0pt;font-family:"Calibri","sans-serif";color:black}span.di{font-size:11.0pt;font-family:"Calibri","sans-serif"}span.dj{font-family: "Calibri","sans-serif"; font-size: 11.0pt; font-weight: bold}p.dk{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;font-weight: bold; text-align: justify}span.co{font-size:11.0pt; font-family:"Calibri","sans-serif";color:black} table.dl{width:411.1pt}td.ck{padding:0cm 0cm 0cm 0cm}p.dm{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;font-weight: bold}span.cm{font-size:11.0pt;font-family: "Calibri","sans-serif";color:black}td.ci{width:25.5%;padding:0cm 0cm 0cm 0cm}span.cj{font-size:11.0pt;font-family:"Calibri","sans-serif"; color:black}span.dn{font-family:"Calibri","sans-serif";color:black;font-size:11.0pt}p.cf{margin-top:0cm;margin-right:0cm;margin-bottom:15.0pt;margin-left: 0cm;text-align:justify;background:white}p.do{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;text-align:justify}span.dp{font-size:11.0pt;font-family:"Calibri","sans-serif"} tr.bx{height:2.3pt}td.ca{width:8.3pt;border:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:2.3pt}p.dq{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;margin-bottom:10.0pt;line-height:115%}span.cd{font-size:10.0pt;line-height:115%;font-family:"Calibri","sans-serif"; color:black}span.cc{font-size:10.0pt;line-height:115%; font-family:"Calibri","sans-serif"}td.by{width:379.95pt;border:solid windowtext 1.0pt; border-left:none;padding:0cm 5.4pt 0cm 5.4pt;height:2.3pt}p.dr{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;font-weight: bold; line-height: 115%; margin-bottom: 10.0pt}tr.bs{height:3.0pt}td.bw{width:8.3pt;border:solid windowtext 1.0pt; border-top:none;padding:0cm 5.4pt 0cm 5.4pt;height:3.0pt}td.bv{width:116.05pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:3.0pt} td.bt{width:253.1pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:3.0pt}span.bu{font-size:10.0pt;line-height:115%;font-family:"Calibri","sans-serif"}td.br{width:8.3pt;border:solid windowtext 1.0pt; border-top:none;padding:0cm 5.4pt 0cm 5.4pt}td.bp{width:379.95pt;border-top:none; border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}span.bq{font-size: 10.0pt;line-height:115%;font-family:"Calibri","sans-serif"}td.bo{width:116.05pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}td.bn{width:253.1pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}span.bm{font-size:9.0pt;line-height:115%;font-family:"Calibri","sans-serif"; color:black}span.bl{font-size:10.0pt; line-height:115%;font-family:"Calibri","sans-serif"}table.ds{border-collapse:collapse} tr.bi{height:9.25pt}td.bk{width:88.8pt;border:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:9.25pt}td.bj{width:88.8pt;border:solid windowtext 1.0pt; border-left:none;padding:0cm 5.4pt 0cm 5.4pt;height:9.25pt}tr.bf{height:11.95pt}td.bh{width:88.8pt;border:solid windowtext 1.0pt; border-top:none;padding:0cm 5.4pt 0cm 5.4pt;height:11.95pt}td.bg{width:88.8pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:11.95pt}span.bd{font-size:11.0pt; font-family:"Calibri","sans-serif";color:red} /**/
RNS Number : 5752Y
ReNeuron Group plc
09 May 2019
 

 

 

9 May 2019

AIM: RENE

 

ReNeuron Group plc

 

Exercise of options, PDMR dealing and

total voting rights

 

ReNeuron Group plc (the "Company") (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, announces that it has received notices to exercise options from certain PDMRs of the Company to subscribe for a total of 65,792 new ordinary shares of 1 pence each in the Company ("Ordinary Shares").

 

On 9 May 2019, Sharon Grimster, VP Development and General Manager Wales, exercised options over 39,960 Ordinary Shares at an exercise price of 100 pence per share. Subsequently, on 9 May 2019, Mrs Grimster sold 39,960 Ordinary Shares at a share price of 267 pence.

 

On 9 May 2019, Dr Randolph Corteling, Head of Research, exercised options over 25,832 Ordinary Shares at an exercise price of 100 pence per share. Subsequently, on 9 May 2019, Dr Corteling sold 25,832 Ordinary Shares at a share price of 267 pence.

 

Total voting rights

Following the issue of 65,792 Ordinary Shares pursuant to the exercise of options described above, together with exercise of options by other staff under its existing blocklisting arrangements, the Company has 31,799,617 ordinary shares of 1 pence each in issue, all with voting rights. The Company holds no ordinary shares in treasury. The above figure of 31,799,617 may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change in their interest in, the Company under the FCA's Disclosure and Transparency Rules.

  

 

ENDS

ENQUIRIES:

 

ReNeuron

+44 (0)20 3819 8400

Olav Hellebø, Chief Executive Officer


Michael Hunt, Chief Financial Officer

 


 

Buchanan

+44 (0) 20 7466 5000

Mark Court, Sophie Wills, Tilly Abraham

 






Stifel Nicolaus Europe Limited

+44 (0) 20 7710 7600

Jonathan Senior, Stewart Wallace, Ben Maddison


(NOMAD and Joint Broker)

 


N+1 Singer

+44 (0) 20 7496 3000

Aubrey Powell, Mark Taylor (Joint Broker)


 

 

 

About ReNeuron

ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments, without the need for immunosuppressive drugs.  The Company's lead clinical-stage candidates are in development for disability as a result of stroke and for the blindness-causing disease, retinitis pigmentosa.  ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that would otherwise be unable to reach their site of action.  ReNeuron's shares are traded on the London AIM market under the symbol RENE.L.  For further information visit www.reneuron.com.

The notifications set out below are provided in accordance with the requirements of the EU Market Abuse Regulation and provide further detail.

 

 

1 

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Sharon Grimster

2

Reason for the notification 

a)

Position/status 

VP Development and General Manager Wales

b)

Initial notification /Amendment 

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name 

ReNeuron Group plc

b)

LEI  

2138003TU12CQ5TZO137

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument 

Identification code 

Ordinary Shares of 1 pence each

 

RENE - GB00BF5G6K95

b)

Nature of the transaction 

Exercise of options over ordinary shares

c)

Price(s) and volume(s)

 

 Price(s) 

Volume(s)

100 pence

39,960

 

d)

 

Aggregated information 

 

N/A

e)

Date of the transaction 

09 May 2019

f)

Place of the transaction 

London Stock Exchange, AIM Market

 

 

 

1 

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Sharon Grimster

2

Reason for the notification 

a)

Position/status 

VP Development and General Manager Wales

b)

Initial notification /Amendment 

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name 

ReNeuron Group plc

b)

LEI  

2138003TU12CQ5TZO137

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument 

Identification code 

Ordinary Shares of 1 pence each

 

RENE - GB00BF5G6K95

b)

Nature of the transaction 

Sale of ordinary shares

c)

Price(s) and volume(s)

 

 Price(s) 

Volume(s)

267 pence

39,960

 

d)

 

Aggregated information 

 

N/A

e)

Date of the transaction 

09 May  2019

f)

Place of the transaction 

London Stock Exchange, AIM Market

 

 

1 

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Randolph Corteling

2

Reason for the notification 

a)

Position/status 

Head of Research

b)

Initial notification /Amendment 

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name 

ReNeuron Group plc

b)

LEI  

2138003TU12CQ5TZO137

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument 

Identification code 

Ordinary Shares of 1 pence each

 

RENE - GB00BF5G6K95

b)

Nature of the transaction 

Exercise of options over ordinary shares

c)

Price(s) and volume(s)

 

 Price(s) 

Volume(s)

100 pence

25,832

 

d)

 

Aggregated information 

 

N/A

e)

Date of the transaction 

09 May 2019

f)

Place of the transaction 

London Stock Exchange, AIM Market

 

 

1 

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Randolph Corteling

2

Reason for the notification 

a)

Position/status 

Head of Research

b)

Initial notification /Amendment 

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name 

ReNeuron Group plc

b)

LEI  

2138003TU12CQ5TZO137

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument 

Identification code 

Ordinary Shares of 1 pence each

 

RENE - GB00BF5G6K95

b)

Nature of the transaction 

Sale of ordinary shares

c)

Price(s) and volume(s)

 

 Price(s) 

Volume(s)

267 pence

25,832

 

d)

 

Aggregated information 

 

N/A

e)

Date of the transaction 

09 May  2019

f)

Place of the transaction 

London Stock Exchange, AIM Market

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
MSCEAKSNEEANEFF

Quick facts: ReNeuron Group PLC

Price: £1.95

Market: LSE
Market Cap: £62.07 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Investor Update: Asiamet signs agreement with China Nonferrous Metals

Headlines from the Proactive UK newsroom. Asiamet (LON:ARS) has teamed up with China Nonferrous Metals to carry out an engineering evaluation on the BKM Copper project in Indonesia.  China NFC is currently building a zinc mine in Sumatra and is looking to expand its activities in the...

3 weeks, 4 days ago